Kathryn C. Arbour, MD
Thoracic Medical Oncologist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
My Specialties
- Lung Cancer
- Targeted Therapy for Lung Cancer
- Immunotherapy for Lung Cancer
Request an Appointment
About Me
- Assistant Attending Physician
I am a medical oncologist whose practice is focused on caring for people with lung cancer. I have particular expertise in identifying patients who may benefit from immunotherapy or targeted therapy and incorporating these advanced therapies into their treatment plans.
I am also actively involved in clinical trials to find newer and better ways to treat lung cancer.
Read more
People with lung cancer are often concerned with how their treatment will impact their day-to-day life. At MSK, our multidisciplinary team of experts is focused on effectively treating our patients’ disease in a way that helps them keep doing the things they love. Using the most advanced therapies in the field, we work together to design treatment plans that minimize side effects to make sure this can happen.
A thoracic medical oncologist is a cancer doctor who specializes in thoracic (thor-A-sik) cancers. These are cancers that have to do with the chest, including lung, tracheal (windpipe), and thymic (thymus) cancers.
My Specialties
- Lung Cancer
- Targeted Therapy for Lung Cancer
- Immunotherapy for Lung Cancer
- Clinical Trials
Education
- MD, Weill Cornell Medical College
Residencies
- Internal Medicine - NewYork-Presybeterian/Weill Cornell Medical Center
- Chief Resident - Memorial Sloan Kettering Cancer Center
Awards and Honors
- ASCO Young Investigator Award (2018)
Fellowships
- Medical Oncology - Memorial Sloan Kettering Cancer Center
Board Certifications
- Internal Medicine
- Medical Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
PPO
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
PPO, HMO, DSN
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
New Patients
Current Patients
Contact and Location
Dr. Arbour sees patients at one location.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Arbour
- A Phase 1B Study of RMC-6291 Plus RMC-6236 in People With Advanced Cancer
- A Phase 3 Study of LY3537982, Pembrolizumab Immunotherapy, and Other Standard Therapies in People With Advanced Non-Small Cell Lung Cancer
- A Phase I Study of RMC-6236 in People with Advanced Solid Tumors Containing Specific KRAS Mutations
- A Phase I/II Study of MRTX1719 in People with Solid Tumors
Read more
- Clinical Trials Co-Investigated by Dr. Arbour
- A Phase 1 Study of RMC-9805 in People With Solid Tumors
- A Phase 2 Study of Sotorasib to Treat Advanced KRAS G12C-Mutant Non-Small Cell Lung Cancer
- A Phase 3 Study of Ivonescimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy as Initial Treatment for Advanced Lung Cancer
- A Phase I Study of ASP3082 in People with Solid Tumors with KRAS G12D Mutations
- A Phase IB Study of AMG 510 Combined with Other Drugs to Treat Metastatic Solid Tumors with the KRAS G12C mutation
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Arbour KC, Jordan E, Kim HR, Dienstag J, Yu HA, Sanchez-Vega F, Lito P, Berger M, Solit DB, Hellmann M, Kris MG, Rudin CM, Ni A, Arcila M, Ladanyi M, Riely GJ. Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer. Clin Cancer Res. 2018 Jan 15;24(2):334-340. doi: 10.1158/1078-0432.CCR-17-1841. Epub 2017 Oct 31.
Patient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Kathryn C. Arbour discloses the following relationships and financial interests:
-
Amgen
Professional Services and Activities -
AstraZeneca
Professional Services and Activities -
G1 Therapeutics
Professional Services and Activities -
Genzyme
Professional Services and Activities -
i3 Health
Professional Services and Activities
-
Lilly Oncology
Professional Services and Activities -
Medscape
Professional Services and Activities -
Novartis
Professional Services and Activities -
Sanofi-Aventis U.S. LLC
Professional Services and Activities -
The Jackson Laboratory
Professional Services and Activities
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.